医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kheiron’s AI Breast Screening Solution Mia® Receives Regulatory Clearance in Australia and New Zealand

2021年06月15日 AM07:00
このエントリーをはてなブックマークに追加


 

LONDON

Marking a new milestone for artificial intelligence (AI) adoption in the Australian and New Zealand breast screening community, the Mia® solution, created by United Kingdom-based Kheiron Medical Technologies, received Therapeutic Goods Administration (TGA) clearance from the Australian Government Department of Health and MedSafe WAND Notification from the New Zealand Ministry of Health as an AI-enabled independent reader for the early detection and diagnosis of breast cancer. Mia is being launched in partnership with AI Advance, an AI consulting services and software distribution company for the medical imaging industry based in Australia and New Zealand.

“Our mission at Kheiron is to support breast screening professionals in the fight against breast cancer with proven and effective AI-enabled tools,” states Alex Hamlow, Kheiron’s chief commercial officer. “We’re excited that Mia is the first AI independent reader solution available for use within the breast screening community in Australia and New Zealand. Based on its performance in the UK and Europe, Mia represents a major breakthrough in helping radiologists to dramatically improve breast cancer detection and patient outcomes.”

With patented AI technology developed on more than three million breast images, Mia (Mammography Intelligent Assessment) is designed to support breast radiologists in making the decision about whether or not to recall women for further testing based on their mammography screening. It was created to deliver gold standard double-reading quality with a single human reader and can also function as an independent second reader, a concurrent reader, or in double reader triage.

“We are looking forward to bringing the Mia solution to the breast screening community throughout Australia and New Zealand,” comments Peter Rady, director and co-founder of AI Advance. “It has tremendous potential to transform the breast screening pathway by empowering breast screening professionals to detect potential malignancies more accurately and quickly, ultimately saving more lives in the fight against breast cancer.”

Mia’s effectiveness has been proven in one of the most ambitious clinical studies in radiology AI to date and tested across multiple demographics and mammography devices. It was one of the recipients of the UK Government’s first AI in Health and Care Awards through which Mia is undergoing multiple deployments and clinical studies across 15 sites in the UK as a benchmark for how to integrate new, cutting edge technologies into the NHS safely and effectively. Kheiron and AI Advance are currently working with an Australian breast-screening provider to establish the protocols for a forthcoming clinical trial, details of which will soon be announced.

About Kheiron Medical Technologies

Founded in 2016 by Peter Kecskemethy and Tobias Rijken, Kheiron Medical Technologies is an applied science company focused on supporting cancer diagnostics with machine learning that works with radiologists so that every patient has a better fighting chance. Its initial focus is improving the outcomes for the more than two million women diagnosed globally every year with breast cancer. Operating in the United Kingdom, United States, and Europe, Kheiron is an international, multi-disciplinary team of senior clinicians, industry experts, engineers and machine learning scientists.

About AI Advance

Based in Melbourne, Australia, and Auckland, New Zealand, AI Advance supplies AI consulting services and products to the medical industry to assist physicians, their referrers, and their patients. Driven by the vision to use AI to benefit humanity, the company combines its experience in medical imaging technology with knowledge of how to apply clinically proven AI solutions to improve patient outcomes in both public and private medical imaging practices.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005737/en/

CONTACT

Gina Mehmert

VP, Global Commercial Marketing

Kheiron Medical Technologies

gina@kheironmed.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Synaffix宣布与普方生物达成价值2.46亿美元的ADC合作
  • Aurion Biotech Announces IOTA Cell Therapy Trial
  • rf IDEAS将在HIMSS21展会上展示与医疗合作伙伴的合作成果
  • rfアイデアズがHIMSS21でヘルスケアパートナーとの協業を紹介
  • Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s